Hospital
Prisma Health-Midlands
Prisma Health-Midlands was paid $68.26M by Medicaid between Jan 2018 and Dec 2024, across 562 billing codes. Its largest line is 36415, Collection of venous blood by venipuncture — 8.4% of everything it billed.
33Billing provider infoPRISMA HEALTH-MIDLANDS
COLUMBIA, SC 29203
COLUMBIA, SC 29203
33aNPI1487868097assigned 05/10/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$68.26M
24GClaims1,764,832
24DCodes billed562
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#5 of 115
Median peer was paid$2.47M
This provider vs. median28×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MILLER, POLLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 234,313 | $9.31M | |
| 2019 | 245,838 | $9.12M | |
| 2020 | 195,312 | $7.96M | |
| 2021 | 290,239 | $10.20M | |
| 2022 | 317,955 | $10.63M | |
| 2023 | 258,803 | $10.05M | |
| 2024incomplete | 222,372 | $10.99M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 36415 | Collection of venous blood by venipuncture | 8.4% | 52,573 | 42,198 | $5.70M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 8.0% | 84,385 | 26,182 | $5.47M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 4.2% | 2,692 | 2,536 | $2.86M |
| 80048 | Basic metabolic panel (calcium, ionized) | 4.0% | 42,331 | 32,629 | $2.73M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.7% | 51,876 | 44,788 | $2.55M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.5% | 19,818 | 12,106 | $2.40M |
| 80053 | Comprehensive metabolic panel | 3.2% | 40,782 | 33,868 | $2.15M |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 2.8% | 3,533 | 3,263 | $1.93M |
| 84156 | 2.5% | 1,761 | 1,506 | $1.70M | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.3% | 12,535 | 11,602 | $1.60M |
| 81025 | 2.3% | 15,698 | 14,357 | $1.55M | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.2% | 32,589 | 26,566 | $1.53M |
550 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | 2.2% | 18,835 | $1.50M |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.0% | 9,274 | $1.36M |
| 80069 | 2.0% | 10,443 | $1.36M | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.0% | 29,027 | $1.34M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.9% | 12,645 | $1.26M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.8% | 16,110 | $1.26M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.7% | 7,824 | $1.16M |
| 81003 | 1.5% | 13,764 | $1.05M | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.5% | 7,254 | $1.01M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.4% | 2,019 | $953K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.3% | 11,226 | $883K |
| 86850 | 1.1% | 10,176 | $757K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.1% | 12,616 | $734K |
| 95782 | 1.0% | 777 | $715K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.0% | 18,047 | $713K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.0% | 9,373 | $710K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 20,691 | $646K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 7,551 | $595K |
| 82570 | <1% | 4,576 | $543K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 13,927 | $518K |
| 99284 | Emergency room visit (serious) | <1% | 29,132 | $477K |
| 74018 | <1% | 7,669 | $460K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,958 | $456K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 14,680 | $407K |
| 81001 | <1% | 27,960 | $387K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 8,869 | $368K |
| 76770 | <1% | 2,599 | $322K | |
| 97161 | <1% | 9,569 | $298K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 15,203 | $295K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,962 | $292K |
| 82565 | <1% | 1,652 | $257K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 2,672 | $250K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 8,859 | $249K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,317 | $248K |
| 93971 | <1% | 1,499 | $241K | |
| 85347 | <1% | 1,828 | $241K | |
| 36416 | <1% | 2,996 | $241K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,469 | $232K |
| 87081 | <1% | 4,490 | $225K | |
| 86900 | <1% | 10,909 | $218K | |
| 71250 | <1% | 1,086 | $217K | |
| 87481 | <1% | 624 | $215K | |
| 99285 | Emergency room visit (most serious) | <1% | 21,338 | $212K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,859 | $211K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,770 | $200K |
| 95951 | <1% | 1,322 | $196K | |
| 87210 | <1% | 3,607 | $196K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 4,885 | $196K |
| 92526 | <1% | 4,272 | $191K | |
| 84702 | <1% | 4,880 | $186K | |
| 92551 | <1% | 2,366 | $184K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 74,008 | $180K |
| 72141 | <1% | 252 | $173K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,297 | $170K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 487 | $167K |
| 93922 | <1% | 1,479 | $164K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 2,852 | $161K |
| 74230 | <1% | 1,346 | $161K | |
| G0378 | Hospital observation service, per hour | <1% | 19,088 | $152K |
| 70250 | <1% | 436 | $149K | |
| 93888 | <1% | 295 | $145K | |
| 43762 | <1% | 1,421 | $141K | |
| 87480 | <1% | 1,937 | $139K | |
| 73130 | <1% | 2,175 | $136K | |
| 87077 | <1% | 6,243 | $135K | |
| 87070 | <1% | 3,201 | $127K | |
| 71045 | Radiologic examination, chest; single view | <1% | 12,154 | $124K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 2,727 | $118K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,417 | $117K |
| 76830 | Ultrasound, transvaginal | <1% | 1,101 | $113K |
| 76870 | <1% | 330 | $108K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 4,974 | $105K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 2,251 | $105K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 28,381 | $104K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,745 | $100K |
| 95813 | <1% | 614 | $99K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 135 | $96K |
| 73630 | <1% | 2,259 | $95K | |
| 43760 | <1% | 273 | $95K | |
| 73560 | <1% | 2,479 | $94K | |
| A4649 | Surgical supply; miscellaneous | <1% | 640 | $93K |
| 80061 | Lipid panel | <1% | 11,324 | $93K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 269 | $93K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,941 | $93K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 3,545 | $92K |
| 86780 | <1% | 7,170 | $88K | |
| 73110 | <1% | 1,227 | $83K | |
| 93970 | <1% | 543 | $82K | |
| 73610 | <1% | 1,706 | $81K | |
| 93880 | <1% | 632 | $80K | |
| 76376 | <1% | 403 | $78K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 8,757 | $77K |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 1,996 | $77K |
| 85018 | <1% | 3,018 | $75K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,106 | $74K |
| 73030 | <1% | 1,910 | $74K | |
| 85027 | <1% | 16,216 | $73K | |
| 73090 | <1% | 704 | $73K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,379 | $72K |
| 74019 | <1% | 1,681 | $70K | |
| 72040 | <1% | 1,226 | $69K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,408 | $66K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,852 | $65K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,449 | $65K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 439 | $59K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,913 | $58K |
| 93017 | <1% | 2,364 | $55K | |
| 97165 | <1% | 1,960 | $55K | |
| 83655 | <1% | 1,177 | $52K | |
| 76536 | <1% | 471 | $51K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 454 | $50K |
| 70496 | <1% | 581 | $50K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,839 | $49K |
| 84703 | <1% | 952 | $48K | |
| 72100 | <1% | 1,629 | $47K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 12,488 | $47K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,018 | $45K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,485 | $44K |
| 86902 | <1% | 2,135 | $43K | |
| 75809 | <1% | 103 | $41K | |
| 95700 | <1% | 481 | $41K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,278 | $40K |
| 97162 | <1% | 1,423 | $40K | |
| 76937 | <1% | 2,729 | $38K | |
| 73502 | <1% | 1,156 | $38K | |
| 86140 | <1% | 6,450 | $37K | |
| 88304 | <1% | 2,752 | $36K | |
| 73590 | <1% | 998 | $36K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,317 | $35K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 514 | $34K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 436 | $34K |
| 12011 | <1% | 291 | $32K | |
| 92523 | <1% | 859 | $32K | |
| 80074 | <1% | 1,727 | $32K | |
| 82043 | <1% | 2,924 | $32K | |
| 95716 | <1% | 214 | $30K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 5,065 | $28K |
| 36591 | <1% | 1,628 | $28K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 8,588 | $28K |
| 93925 | <1% | 511 | $28K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 161 | $28K |
| 77072 | <1% | 675 | $27K | |
| 94760 | <1% | 2,971 | $27K | |
| 76000 | <1% | 1,166 | $26K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 3,274 | $25K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 240 | $25K |
| 82272 | <1% | 740 | $24K | |
| 76642 | <1% | 438 | $24K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 513 | $24K |
| 84439 | <1% | 3,885 | $23K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,913 | $23K |
| 93458 | <1% | 709 | $22K | |
| 80081 | <1% | 464 | $22K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 12,262 | $22K |
| 84145 | <1% | 3,156 | $21K | |
| 85610 | <1% | 11,148 | $19K | |
| 80076 | <1% | 3,415 | $18K | |
| 54360 | <1% | 169 | $18K | |
| 93926 | <1% | 371 | $18K | |
| 87428 | <1% | 206 | $18K | |
| 73070 | <1% | 140 | $18K | |
| 82728 | <1% | 4,580 | $18K | |
| 97597 | <1% | 603 | $18K | |
| C1769 | Guide wire | <1% | 2,838 | $17K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,576 | $17K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 279 | $17K |
| 12001 | <1% | 144 | $16K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 718 | $16K |
| 85660 | <1% | 1,214 | $16K | |
| 82950 | <1% | 2,078 | $15K | |
| 76801 | <1% | 1,274 | $15K | |
| 92610 | <1% | 812 | $15K | |
| 76885 | <1% | 104 | $15K | |
| 10060 | <1% | 128 | $15K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,001 | $15K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 30 | $15K |
| 82550 | <1% | 2,897 | $14K | |
| 85014 | <1% | 953 | $14K | |
| 89051 | <1% | 452 | $14K | |
| 84484 | <1% | 13,256 | $14K | |
| 95811 | <1% | 50 | $14K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,884 | $14K |
| 73080 | <1% | 27 | $14K | |
| 80177 | <1% | 1,053 | $13K | |
| 90686 | <1% | 6,386 | $13K | |
| 74022 | <1% | 458 | $13K | |
| 99174 | <1% | 194 | $13K | |
| 83735 | <1% | 22,513 | $12K | |
| 59025 | Fetal non-stress test | <1% | 279 | $12K |
| 70360 | <1% | 161 | $12K | |
| 84132 | <1% | 1,442 | $11K | |
| 88142 | <1% | 1,638 | $11K | |
| 70486 | <1% | 248 | $11K | |
| 74183 | <1% | 12 | $10K | |
| 97113 | <1% | 407 | $10K | |
| 87807 | <1% | 232 | $10K | |
| 86901 | <1% | 10,933 | $10K | |
| 36600 | <1% | 221 | $9K | |
| 87641 | <1% | 460 | $9K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 459 | $9K |
| 17250 | <1% | 31 | $9K | |
| 83037 | <1% | 683 | $8K | |
| J3490 | Unclassified drugs | <1% | 14,577 | $8K |
| 97116 | <1% | 2,723 | $8K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 133 | $8K |
| 83020 | <1% | 4,585 | $8K | |
| 82607 | <1% | 2,062 | $8K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 30,967 | $7K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 4,381 | $7K |
| 87631 | <1% | 965 | $7K | |
| 75574 | <1% | 119 | $7K | |
| 87040 | <1% | 3,421 | $7K | |
| 82247 | <1% | 127 | $7K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,122 | $7K |
| 0002A | <1% | 272 | $7K | |
| 96523 | <1% | 151 | $7K | |
| 83001 | <1% | 281 | $7K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,569 | $6K |
| 82657 | <1% | 346 | $6K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 194 | $6K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 9,445 | $6K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 2,632 | $6K |
| 95957 | <1% | 992 | $6K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,185 | $6K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 2,056 | $6K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 21,831 | $5K |
| 97166 | <1% | 125 | $5K | |
| 74455 | <1% | 24 | $5K | |
| 73552 | <1% | 244 | $5K | |
| 99381 | <1% | 76 | $5K | |
| 69209 | <1% | 12 | $5K | |
| 86803 | <1% | 4,641 | $5K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 14,893 | $5K |
| 82330 | <1% | 919 | $5K | |
| 90656 | <1% | 543 | $5K | |
| 93325 | <1% | 176 | $5K | |
| 72156 | <1% | 13 | $5K | |
| 86580 | <1% | 354 | $5K | |
| 70498 | <1% | 618 | $5K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,496 | $5K |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 82 | $5K |
| 82105 | <1% | 386 | $5K | |
| 76886 | <1% | 26 | $5K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 190 | $4K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,147 | $4K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 15,946 | $4K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 53 | $4K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 69 | $4K |
| 86361 | <1% | 509 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,646 | $4K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 37 | $4K |
| 70491 | <1% | 39 | $4K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 7,702 | $4K |
| 93226 | <1% | 14 | $4K | |
| 96367 | <1% | 673 | $4K | |
| 82945 | <1% | 20 | $4K | |
| 86592 | <1% | 585 | $4K | |
| 83516 | <1% | 408 | $4K | |
| 72170 | <1% | 167 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 23,430 | $4K |
| 85379 | <1% | 831 | $4K | |
| 83540 | <1% | 3,113 | $4K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 347 | $4K |
| 86920 | <1% | 3,213 | $4K | |
| 76818 | <1% | 182 | $3K | |
| 82805 | <1% | 1,350 | $3K | |
| 99173 | <1% | 570 | $3K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 515 | $3K |
| 84146 | <1% | 256 | $3K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 60 | $3K |
| 76775 | <1% | 31 | $3K | |
| 93297 | <1% | 86 | $3K | |
| 93923 | <1% | 12 | $3K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 365 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,556 | $3K |
| 0072A | <1% | 103 | $3K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 3,610 | $3K |
| 80143 | <1% | 153 | $3K | |
| 90715 | <1% | 3,628 | $3K | |
| 82784 | <1% | 870 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,178 | $3K |
| 85730 | <1% | 6,263 | $3K | |
| 86706 | <1% | 895 | $3K | |
| 77066 | Tomosynthesis, mammo | <1% | 33 | $3K |
| 87015 | <1% | 29 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,532 | $2K |
| 11982 | <1% | 13 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,826 | $2K |
| 82040 | <1% | 132 | $2K | |
| 83690 | <1% | 8,613 | $2K | |
| 94664 | <1% | 3,424 | $2K | |
| 86704 | <1% | 385 | $2K | |
| 86480 | <1% | 421 | $2K | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 45 | $2K |
| 83880 | <1% | 4,567 | $2K | |
| 0001A | <1% | 336 | $2K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 531 | $2K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 6,071 | $2K |
| 90620 | <1% | 497 | $2K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 165 | $2K |
| 72146 | <1% | 12 | $2K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,962 | $2K |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,298 | $2K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,057 | $2K |
| 93299 | <1% | 31 | $2K | |
| 90647 | <1% | 1,813 | $2K | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 39 | $2K |
| 96376 | <1% | 7,856 | $2K | |
| 88300 | <1% | 91 | $2K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 3,906 | $2K |
| 80164 | <1% | 240 | $2K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 319 | $1K |
| 0071A | <1% | 154 | $1K | |
| 92609 | <1% | 128 | $1K | |
| 95816 | <1% | 14 | $1K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 819 | $1K |
| 87340 | <1% | 5,172 | $1K | |
| 83615 | <1% | 1,864 | $1K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 552 | $1K |
| 87205 | <1% | 2,979 | $1K | |
| 36430 | <1% | 3,819 | $1K | |
| 74240 | <1% | 12 | $1K | |
| 29515 | <1% | 58 | $1K | |
| 82140 | <1% | 47 | $1K | |
| 86762 | <1% | 2,514 | $1K | |
| 80197 | <1% | 457 | $1K | |
| 76882 | <1% | 15 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 10,675 | $1K |
| 90633 | <1% | 1,790 | $1K | |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 660 | $1K |
| 83993 | <1% | 26 | $953.57 | |
| 82785 | <1% | 91 | $896.77 | |
| 94010 | <1% | 12 | $893.62 | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 140 | $876.33 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,740 | $850.69 |
| 90670 | <1% | 2,164 | $835.73 | |
| 84100 | <1% | 5,496 | $828.49 | |
| 90651 | <1% | 1,113 | $817.29 | |
| 73060 | <1% | 54 | $770.16 | |
| 0004A | <1% | 206 | $763.60 | |
| 72070 | <1% | 30 | $735.26 | |
| 76641 | <1% | 12 | $719.45 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 7,811 | $695.42 |
| 87536 | <1% | 565 | $695.22 | |
| 74220 | <1% | 12 | $676.95 | |
| 88307 | <1% | 122 | $662.65 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 84 | $649.18 |
| 87486 | <1% | 49 | $617.86 | |
| 82670 | <1% | 38 | $614.46 | |
| 82310 | <1% | 120 | $571.75 | |
| 83605 | <1% | 3,183 | $543.03 | |
| 88342 | <1% | 685 | $540.64 | |
| 87522 | Neg quan hep c or qual rna | <1% | 121 | $538.32 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,144 | $532.40 |
| 82248 | <1% | 338 | $529.91 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,197 | $517.62 |
| 99152 | <1% | 1,374 | $514.11 | |
| 90677 | <1% | 958 | $504.86 | |
| 76857 | <1% | 81 | $504.38 | |
| A9270 | Non-covered item or service | <1% | 9,450 | $502.16 |
| 99188 | <1% | 265 | $501.55 | |
| 85652 | <1% | 3,630 | $490.01 | |
| 86038 | <1% | 398 | $473.43 | |
| 90662 | <1% | 521 | $467.24 | |
| 82746 | <1% | 1,082 | $428.18 | |
| 0124A | <1% | 510 | $393.20 | |
| H0002 | Behavioral health screening to determine eligibility for admission to treatment program | <1% | 15 | $375.72 |
| 99205 | Prolong outpt/office vis | <1% | 13 | $363.13 |
| 0054A | <1% | 232 | $355.86 | |
| 90685 | <1% | 400 | $324.58 | |
| 86870 | <1% | 15 | $317.48 | |
| 91320 | <1% | 442 | $286.82 | |
| 87102 | <1% | 41 | $284.68 | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 268 | $282.96 |
| 86923 | <1% | 1,090 | $257.99 | |
| 85045 | <1% | 9,633 | $249.26 | |
| 80162 | <1% | 14 | $242.40 | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 17 | $240.46 |
| 82627 | <1% | 28 | $221.53 | |
| 86682 | <1% | 120 | $220.74 | |
| 82962 | <1% | 17 | $213.25 | |
| 86003 | <1% | 96 | $206.49 | |
| 82947 | <1% | 233 | $198.18 | |
| 84403 | <1% | 184 | $196.56 | |
| 90649 | <1% | 489 | $195.18 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 515 | $184.69 |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 50 | $160.14 |
| 90746 | <1% | 31 | $153.58 | |
| 0081A | <1% | 41 | $122.22 | |
| 90480 | <1% | 510 | $122.22 | |
| 36592 | <1% | 29 | $121.93 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 263 | $121.93 |
| 84550 | <1% | 180 | $118.37 | |
| 90723 | <1% | 1,777 | $112.62 | |
| 90734 | <1% | 1,394 | $107.91 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 57 | $107.79 |
| 84481 | <1% | 330 | $94.17 | |
| 90682 | <1% | 154 | $93.42 | |
| 82077 | <1% | 901 | $90.00 | |
| 90700 | <1% | 116 | $88.21 | |
| 92611 | <1% | 1,197 | $85.94 | |
| 0154A | <1% | 28 | $77.78 | |
| 90696 | <1% | 162 | $65.74 | |
| 0051A | <1% | 14 | $40.74 | |
| 90707 | <1% | 122 | $38.00 | |
| 86708 | <1% | 178 | $35.85 | |
| 87116 | <1% | 38 | $34.92 | |
| 84425 | <1% | 596 | $30.11 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 2,254 | $30.11 |
| 86787 | <1% | 456 | $26.42 | |
| 85576 | <1% | 44 | $22.64 | |
| 87075 | <1% | 290 | $19.47 | |
| 84134 | <1% | 543 | $18.80 | |
| 90710 | <1% | 140 | $18.00 | |
| 84295 | <1% | 166 | $15.26 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 41 | $12.88 |
| 86200 | <1% | 56 | $12.58 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 2,599 | $7.27 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 344 | $0.76 |
| J0280 | Injection, aminophyllin, up to 250 mg | 0% | 731 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 1,696 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 1,120 | $0.00 |
| 90716 | 0% | 117 | $0.00 | |
| 87510 | 0% | 1,937 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 1,199 | $0.00 |
| 94644 | 0% | 744 | $0.00 | |
| 86800 | 0% | 25 | $0.00 | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 0% | 1,064 | $0.00 |
| 42830 | 0% | 39 | $0.00 | |
| 36410 | 0% | 1,112 | $0.00 | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | 0% | 1,461 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 1,651 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 735 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 294 | $0.00 |
| 86921 | 0% | 674 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 220 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 1,481 | $0.00 |
| J0697 | Injection, sterile cefuroxime sodium, per 750 mg | 0% | 30 | $0.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 296 | $0.00 |
| G0009 | Administration of pneumococcal vaccine | 0% | 219 | $0.00 |
| 88341 | 0% | 67 | $0.00 | |
| 82553 | 0% | 903 | $0.00 | |
| 86317 | 0% | 101 | $0.00 | |
| G0379 | Direct admission of patient for hospital observation care | 0% | 790 | $0.00 |
| G8998 | Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 15 | $0.00 |
| 90378 | 0% | 314 | $0.00 | |
| 31231 | 0% | 15 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 575 | $0.00 |
| 86160 | 0% | 242 | $0.00 | |
| 83002 | 0% | 195 | $0.00 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 207 | $0.00 |
| 86376 | 0% | 78 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 204 | $0.00 |
| J2780 | Injection, ranitidine hydrochloride, 25 mg | 0% | 16 | $0.00 |
| 86225 | 0% | 31 | $0.00 | |
| 87581 | 0% | 49 | $0.00 | |
| D7140 | Extraction, erupted tooth or exposed root | 0% | 90 | $0.00 |
| 12002 | 0% | 14 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 27 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 16 | $0.00 |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 0% | 13 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 14 | $0.00 |
| 90732 | 0% | 56 | $0.00 | |
| 86255 | 0% | 193 | $0.00 | |
| D1206 | Topical application of fluoride varnish | 0% | 38 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 15 | $0.00 |
| 86364 | 0% | 13 | $0.00 | |
| 84436 | 0% | 57 | $0.00 | |
| 85651 | 0% | 162 | $0.00 | |
| 31622 | 0% | 16 | $0.00 | |
| 83520 | 0% | 12 | $0.00 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 19 | $0.00 |
| 90935 | Hemodialysis procedure with single evaluation by a physician | 0% | 24 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 15 | $0.00 |
| 77001 | 0% | 14 | $0.00 | |
| 84402 | 0% | 16 | $0.00 | |
| 87206 | 0% | 23 | $0.00 | |
| 51600 | 0% | 24 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 17 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 6,343 | $0.00 |
| 86922 | 0% | 1,276 | $0.00 | |
| 87799 | 0% | 757 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 703 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 983 | $0.00 |
| 90461 | 0% | 1,665 | $0.00 | |
| 87660 | 0% | 1,917 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 341 | $0.00 |
| 90681 | 0% | 842 | $0.00 | |
| 87186 | 0% | 4,916 | $0.00 | |
| 86235 | 0% | 59 | $0.00 | |
| 93976 | 0% | 1,973 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 1,693 | $0.00 |
| 84466 | 0% | 2,700 | $0.00 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | 0% | 200 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 130 | $0.00 |
| 80323 | 0% | 54 | $0.00 | |
| 82610 | 0% | 45 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 698 | $0.00 |
| 83970 | 0% | 412 | $0.00 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 48 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 433 | $0.00 |
| D1120 | Dental cleaning, child | 0% | 39 | $0.00 |
| 87512 | 0% | 625 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 357 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 975 | $0.00 |
| S5010 | 5% dextrose and 0.45% normal saline, 1000 ml | 0% | 1,409 | $0.00 |
| 84460 | 0% | 138 | $0.00 | |
| J1598 | Injection, glycopyrrolate (fresenius kabi), not therapeutically equivalent to j1596, 0.1 mg | 0% | 234 | $0.00 |
| 85384 | 0% | 238 | $0.00 | |
| 82010 | 0% | 50 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 261 | $0.00 |
| 82977 | 0% | 283 | $0.00 | |
| 84450 | 0% | 139 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 685 | $0.00 |
| 86431 | 0% | 112 | $0.00 | |
| 88312 | 0% | 16 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 194 | $0.00 |
| G0390 | Trauma response team associated with hospital critical care service | 0% | 50 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 155 | $0.00 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 51 | $0.00 |
| 80179 | 0% | 131 | $0.00 | |
| 86735 | 0% | 134 | $0.00 | |
| 93750 | 0% | 258 | $0.00 | |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | 0% | 50 | $0.00 |
| 86774 | 0% | 129 | $0.00 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 0% | 498 | $0.00 |
| J9370 | Vincristine sulfate, 1 mg | 0% | 22 | $0.00 |
| 86765 | 0% | 133 | $0.00 | |
| 54161 | 0% | 41 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 147 | $0.00 |
| D2934 | 0% | 13 | $0.00 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 14 | $0.00 |
| 94645 | 0% | 16 | $0.00 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 24 | $0.00 |
| 93356 | 0% | 12 | $0.00 | |
| 84305 | 0% | 58 | $0.00 | |
| 86696 | 0% | 14 | $0.00 | |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | 0% | 76 | $0.00 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 0% | 79 | $0.00 |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 0% | 15 | $0.00 |
| 54163 | 0% | 13 | $0.00 | |
| 84590 | 0% | 13 | $0.00 | |
| 95714 | 0% | 64 | $0.00 | |
| D2930 | Prefabricated stainless steel crown - primary tooth | 0% | 16 | $0.00 |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 0% | 48 | $0.00 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 23 | $0.00 |
| 88104 | 0% | 29 | $0.00 | |
| 86705 | 0% | 16 | $0.00 | |
| 84630 | 0% | 18 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 89 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMILLER, POLLY (VP PAYOR STRATEGIES ALIGNMENT)
| Provider | Location | Paid |
|---|---|---|
| Prisma Health-Midlands | Columbia, SC | $74.58M |
| Prisma Health-Upstate | Greenville, SC | $25.04M |
| Prisma Health-Upstate | Greenville, SC | $21.98M |
| Prisma Health-Upstate | Greenville, SC | $19.69M |
| Prisma Health-Upstate | Seneca, SC | $15.64M |
| Prisma Health-Midlands | Columbia, SC | $11.77M |
| Prisma Health-Upstate | Greenville, SC | $10.74M |
| Greenville Health Corporation | Greenville, SC | $8.90M |
| Prisma Health-Upstate | Greenville, SC | $8.32M |
| Prisma Health-Upstate | Greenville, SC | $7.45M |
| Prisma Health University Medical Group | Greenville, SC | $7.44M |
| Prisma Health-Midlands | Coulmbia, SC | $7.43M |
| Prisma Health-Midlands | Columbia, SC | $6.88M |
| Prisma Health Tuomey | Sumter, SC | $6.84M |
| Prisma Health-Midlands | Columbia, SC | $6.77M |
| Prisma Health-Upstate | Greenville, SC | $6.37M |
| Prisma Health-Upstate | Greenville, SC | $5.00M |
| Prisma Health-Upstate | Greenville, SC | $4.65M |
| Prisma Health-Midlands | Columbia, SC | $4.63M |
| Prisma Health-Upstate | Seneca, SC | $4.48M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.